Germany’s New Drug Pricing Law Sticks American Patients With The Bill, But Trump’s Trade Team Is Fighting Back

0
121

Germany has enacted a law that sharply cuts what its government-run healthcare system pays for patented medicines despite repeated warnings from the Trump Administration that the policy dumps the costs of pharmaceutical innovation onto American patients. Washington is not letting it slide. The United States has launched a Section 301 trade investigation that could end in tariffs or other trade measures, making Germany the key test case of whether wealthy “allies” can keep securing artificially low drug prices while U.S. patients fund a wildly disproportionate share of the research and development behind the medicines both countries use.

The law, known as GKV-BStabG, was approved by the Bundestag and Bundesrat in July 2026 with the stated aim of stabilizing Germany’s statutory health insurance system amid projected deficits. At its core is a massive increase in the…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here